SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the 8th Annual H.C. Wainwright MASH Investor Conference on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT).
The live webcast will be available on the Events and Presentations page of Gyre’s website. A webcast replay will be accessible following the live session.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in MASH is based on the company’s experience in MASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.
For Investors:
Stephen Jasper
stephen@gilmartinir.com
KUALA LUMPUR, Malaysia, Oct. 4, 2024 /PRNewswire/ -- EBSWARE, a leading financial technology firm is…
ARLINGTON, Va., Oct. 4, 2024 /PRNewswire/ -- The Bone Health and Osteoporosis Foundation announced that it…
Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to…
The primary driver for the growth of the Disaster Recovery Software Market is the increasing…
The Dana Foundation Launches Neurotech Justice Accelerator at Mass General Brigham (NJAM) to Unite Science…
The developer of the world's first FDA-cleared, smartphone-powered kidney test is being recognized in the…